The bioinformatics startup Culmination Bio had received financial backing from Merck’s venture arm. Now, the Utah-based company is collaborating directly with the pharmaceutical giant on an autoimmune disease research project. According to Culmination Bio‘s CEO Dr. Lincoln Nadauld, the collaboration highlights the value of the startup’s ability to provide rapid access to high-quality longitudinal patient…
Epstein-Barr virus: Trigger and driver of multiple sclerosis?
Recent research has indicated a link between Epstein-Barr virus (EBV) and multiple sclerosis (MS), with some researchers going as far as to say that EBV might be a potential trigger of MS. However, it remains unclear whether the virus also drives the progression of the disease. Current treatments focus largely on moderating inflammation. In this…